Results 201 to 210 of about 28,054 (245)

Erratum for the Research Article "Parkinson's VPS35[D620N] mutation induces LRRK2-mediated lysosomal association of RILPL1 and TMEM55B" by P. Pal <i>et al</i>.

Sci Adv
europepmc   +1 more source

Pathology and Genetics in a Global Cohort of Parkinsonian Disorders.

JAMA Neurol
Wu LY, du Toit T, Georgiades T, Stafford EJ, Levine K, Fang ZH, Jasaityte S, Martinez AG, Cullinane P, De Pablo-Fernandez E, Blauwendraat C, Singleton AB, Scholz SW, Traynor BJ, Wood N, Hardy J, Chinnery P, Houlden H, Cain R, Troakes C, Chelban V, Serrano GE, Gveric D, McLean C, Love S, King A, Robinson AC, Roncaroli F, Shepherd C, Halliday G, Parkkinen L, Morris CM, Smith C, Beach TG, Gentleman S, Warner TT, Lashley T, Jaunmuktane Z, Real R, Morris HR, Global Parkinson’s Genetic Program (GP2).   +40 more
europepmc   +1 more source

Cellular processes associated with LRRK2 function and dysfunction [PDF]

FEBS Journal, 2015
Mutations in the leucine-rich repeat kinase 2 (LRRK2) encoding gene are the most common cause of monogenic Parkinson's Disease (PD). The identification of LRRK2 polymorphisms associated with increased risk for sporadic PD, as well as the observation that
Rebecca L Wallings, Claudia Manzoni, Rina Bandopadhyay   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

LRRK2 and neurodegeneration

Acta Neuropathologica, 2009
Mutations in leucine-rich repeat kinase 2 gene (PARK8/LRRK2) encoding the protein Lrrk2 are causative of inherited and sporadic Parkinson's disease (PD) with phenotypic manifestations of frontotemporal lobar degeneration, corticobasal degeneration and associated motor neuron disease in some patients, and with variable penetrance.
Gabriel, Santpere, Isidre, Ferrer
openaire   +2 more sources

PARK8 LRRK2 parkinsonism

Current Neurology and Neuroscience Reports, 2006
Parkinson's disease (PD) is the most common form of parkinsonism, affecting nearly 2% of people older than 65 years of age. Symptomatic treatment has been available for decades, but to date there is no treatment retarding disease progression. Over the past decade several genes causing parkinsonism have been identified in families with a mendelian ...
Kristoffer, Haugarvoll, Zbigniew K, Wszolek   +1 more
openaire   +2 more sources

LRRK2 and vesicle trafficking

Biochemical Society Transactions, 2012
Mutations in LRRK2 (leucine-rich repeat kinase 2) (also known as PARK8 or dardarin) are responsible for the autosomal-dominant form of PD (Parkinson's disease). LRRK2 mutations were found in approximately 3–5% of familial and 1–3% of sporadic PD cases with the highest prevalence (up to 40%) in North Africans and Ashkenazi Jews.
Sanna, G, Del Giudice, MG, CROSIO, Claudia, IACCARINO, Ciro   +3 more
openaire   +3 more sources

LRRK2 and Autophagy

2017
Leucine-rich repeat kinase 2 (LRRK2) has been implicated in a wide range of cellular processes, including the catabolic pathways collectively described as autophagy. In this chapter, the evidence linking LRRK2 to autophagy will be examined, along with how regulation of autophagy and lysosomal pathways may provide a nexus between the physiological ...
Claudia, Manzoni, Patrick A, Lewis
openaire   +2 more sources

The synaptic function of LRRK2

Biochemical Society Transactions, 2012
Mutations in LRRK2 (leucine-rich repeat kinase 2) are the most frequent genetic lesions so far found in familial as well as sporadic forms of PD (Parkinson's disease), a neurodegenerative disease characterized by the dysfunction and degeneration of dopaminergic and other neuronal types.
Seongsoo, Lee, Yuzuru, Imai, Stephan, Gehrke, Song, Liu, Bingwei, Lu   +4 more
openaire   +2 more sources

LRRK2 and Rab GTPases

Biochemical Society Transactions, 2018
Leucine-rich repeat kinase 2 (LRRK2) is mutated in familial Parkinson's disease, and pathogenic mutations activate the kinase activity. A tour de force screen by Mann and Alessi and co-workers identified a subset of Rab GTPases as bona fide LRRK2 substrates.
openaire   +2 more sources